Sign Out
High doses of glycopyrronium may lead to anticholinergic signs and symptoms for which symptomatic treatment may be indicated.
In COPD patients, repeated orally inhaled administration of SEEBRI BREEZHALER at total doses of 100 and 200 μg once-daily for 28 days were well tolerated.
Acute intoxication by inadvertent oral ingestion of SEEBRI BREEZHALER capsules is unlikely due to the low oral bioavailability (about 5%).
Peak plasma levels and total systemic exposure following i.v. administration of 150 μg glycopyrronium bromide (equivalent to 120 μg glycopyrronium) in healthy volunteers were respectively about 50-fold and 6-fold higher than the peak and total systemic exposure at steady-state achieved with the recommended dose (50 μg once-daily) of SEEBRI BREEZHALER and were well tolerated.
Lanjutkan dengan Google